1. Jul 14, 2020

Visual acuity improvement after aflibercept injection maintained over 3 years

Long-term aflibercept injection achieve visual improvement and reduced the thickness of the retina and choroid in patients with neovascular age-related macular degeneration (nAMD), according to a study published in BMC Ophthalmology.

In this prospective study, 49 patients (50 eyes) with treatment-naïve nAMD received intravitreal aflibercept injection every 2 months for the first year before switching to a treat-and-extend approach in the subsequent 2 years.

Of the 28 patients (29 eyes) who completed the 36 months follow-up, 15 eyes had typical AMD and 14 had polypoidal choroidal vasculopathy.

Over the course of 3 years, the number of ntravitreal aflibercept injections performed was 17.2±3.1 (mean±standard deviation). At baseline, the mean logMAR was 0.42, and improved to 0.19 at 12months and 0.26 at 36months. Central retinal thickness was 329±120μm, 151±38μm, and 143±61μm at baseline, 12 months, and 36 months respectively. The mean subfoveal choroidal thickness (SFCT) was 288±97μm at baseline, 243±82μm at 12months, and 208±63μm at 36months. No difference was noted between typical AMD and polypoidal choroidal vasculopathy.


Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration. BMC Ophthalmol. 2020;20:276. https://doi.org/10.1186/s12886-020-01542-6